ClinicalTrials.gov
ClinicalTrials.gov Menu

Renal Denervation in Patients With Chronic Kidney Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01832233
Recruitment Status : Active, not recruiting
First Posted : April 16, 2013
Last Update Posted : October 24, 2017
Sponsor:
Information provided by (Responsible Party):
Saskatchewan Health Authority - Regina Area

Brief Summary:
People with hypertension are at a higher risk for cardiovascular disease and death so it is important to lower blood pressure to normal levels as quickly as possible. Previous research has established that renal nerve denervation successfully lowers blood pressure measured in the arm in the physician's office. This study is being conducted so that the investigators can determine whether renal nerve denervation also helps to lower blood pressure over 24 hours, as well as central aortic blood pressure, which is pressure exerted by the aorta closer to the heart and may be a better predictor of cardiovascular problems. The investigators also want to know whether these beneficial effects on blood pressure can last up to 2 years, whether renal denervation reduces the number of medications patients need to take, and whether it reduces glucose and insulin levels in the blood since hypertension is also related to obesity and diabetes.

Condition or disease Intervention/treatment Phase
Chronic Kidney Disease Procedure: Renal Denervation Not Applicable

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 26 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Prairie Renal Denervation Study
Study Start Date : January 2013
Actual Primary Completion Date : April 1, 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Diseases
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Renal Denervation
Patients with resistant hypertension and chronic kidney disease (GFR between 15 and 60) will receive Renal Denervation as a treatment
Procedure: Renal Denervation
The Symplicity Renal Denervation System is indicated for the delivery of low-level radiofrequency energy through the wall of the renal artery to denervate the kidney and reduce blood pressure in adult patients with refractory hypertension. The Symplicity Generator delivers controlled relatively low power radiofrequency energy (approximately 8 watts for 2 minutes). The Symplicity System selectively denervates the kidney by delivering radiofrequency from the generator via the electrode of the catheter through the renal artery wall from the intra-luminal side to ablate the renal sympathetic efferent and afferent nerves and reduce overall sympathetic nervous system activity.



Primary Outcome Measures :
  1. Change from Baseline in Central Blood Pressure at 6-months Post-Renal Denervation [ Time Frame: Baseline to 6 months after treatment ]
    measured using ATCOR machine: Augmentation index (%) Augmentation pressure (mm Hg) Central pulse pressure (mm Hg) Central systolic pressure (mm Hg) Central diastolic pressure (mm Hg) Pulse pressure amplification (mm Hg) Time to reflection (Tr) in ms Pulse Wave Velocity


Secondary Outcome Measures :
  1. Change from Baseline in fasting glucose [ Time Frame: Baseline, Post 3, 6, 12, 18, 24 months after renal denervation treatment ]
    fasting blood measures of glucose

  2. Change from Baseline in Cardiac Parameters [ Time Frame: Baseline, Post 12 and 24 months renal denervation treatment ]

    Using an echocardiogram, the following cardiac measures will be taken:

    Left ventricle volume Left ventricle hypertrophy Left ventricle function Left atrial mass E-wave velocity E-prime velocity


  3. Change from Baseline in fasting insulin [ Time Frame: Baseline, Post 3, 6, 12, 18, 24 months after renal denervation treatment. ]
    fasting blood measure of insulin

  4. Change from Baseline in Peripheral Blood Pressure at 3 months Post-Renal Denervation [ Time Frame: Baseline to 3 months after treatment ]
    systolic and diastolic blood pressure (mm Hg) measured using BP-Tru machine.

  5. Change from Baseline in Peripheral Blood Pressure at 6 months Post-Renal Denervation [ Time Frame: Baseline to 6 months after treatment ]
    systolic and diastolic blood pressure (mm Hg) measured using BP-Tru machine

  6. Change from Baseline in Peripheral Blood Pressure at 12-months Post-Renal Denervation [ Time Frame: Baseline to 12 months after treatment ]
    systolic and diastolic blood pressure (mm Hg) measured using BP-Tru machine

  7. Change from Baseline in Peripheral Blood Pressure at 18-months Post-Renal Denervation [ Time Frame: Baseline to 18 months after treatment ]
    systolic and diastolic blood pressure (mm Hg) measured using BP-Tru machine

  8. Change from Baseline in Peripheral Blood Pressure at 24-months Post-Renal Denervation [ Time Frame: Baseline to 24 months after treatment ]
    systolic and diastolic blood pressure (mm Hg) measured using BP-Tru machine

  9. Change from Baseline in Central Blood Pressure at 3-months Post-Renal Denervation [ Time Frame: Baseline to 3 months after treatment ]
    measured using ATCOR machine: Augmentation index (%) Augmentation pressure (mm Hg) Central pulse pressure (mm Hg) Central systolic pressure (mm Hg) Central diastolic pressure (mm Hg) Pulse pressure amplification (mm Hg) Time to reflection (Tr) in ms Pulse Wave Velocity

  10. Change from Baseline in Central Blood Pressure at 12-months Post-Renal Denervation [ Time Frame: Baseline to 12 months after treatment ]
    measured using ATCOR machine: Augmentation index (%) Augmentation pressure (mm Hg) Central pulse pressure (mm Hg) Central systolic pressure (mm Hg) Central diastolic pressure (mm Hg) Pulse pressure amplification (mm Hg) Time to reflection (Tr) in ms Pulse Wave Velocity

  11. Change from Baseline in Central Blood Pressure at 18-months Post-Renal Denervation [ Time Frame: Baseline to 18 months after treatment ]
    measured using ATCOR machine: Augmentation index (%) Augmentation pressure (mm Hg) Central pulse pressure (mm Hg) Central systolic pressure (mm Hg) Central diastolic pressure (mm Hg) Pulse pressure amplification (mm Hg) Time to reflection (Tr) in ms Pulse Wave Velocity

  12. Change from Baseline in Central Blood Pressure at 24-months Post-Renal Denervation [ Time Frame: Baseline to 24 months after treatment ]
    measured using ATCOR machine: Augmentation index (%) Augmentation pressure (mm Hg) Central pulse pressure (mm Hg) Central systolic pressure (mm Hg) Central diastolic pressure (mm Hg) Pulse pressure amplification (mm Hg) Time to reflection (Tr) in ms Pulse Wave Velocity

  13. Change from Baseline in 24-Hour Ambulatory Blood Pressure at 3-months Post-Renal Denervation [ Time Frame: Baseline to 3 months after treatment ]

    For 24-hour blood pressure, we will record the following:

    12-hour daytime Systolic Pressure (mm Hg) 12-hour daytime Diastolic Pressure (mm Hg) 12-hour nighttime Systolic Pressure (mm Hg) 12-hour nighttime Diastolic Pressure (mm Hg)


  14. Change from Baseline in 24-Hour Ambulatory Blood Pressure at 6-months Post-Renal Denervation [ Time Frame: Baseline to 6 months after treatment ]

    For 24-hour blood pressure, we will record the following:

    12-hour daytime Systolic Pressure (mm Hg) 12-hour daytime Diastolic Pressure (mm Hg) 12-hour nighttime Systolic Pressure (mm Hg) 12-hour nighttime Diastolic Pressure (mm Hg)


  15. Change from Baseline in 24-Hour Ambulatory Blood Pressure at 12-months Post-Renal Denervation [ Time Frame: Baseline to 12 months after treatment ]

    For 24-hour blood pressure, we will record the following:

    12-hour daytime Systolic Pressure (mm Hg) 12-hour daytime Diastolic Pressure (mm Hg) 12-hour nighttime Systolic Pressure (mm Hg) 12-hour nighttime Diastolic Pressure (mm Hg)


  16. Change from Baseline in 24-Hour Ambulatory Blood Pressure at 18-months Post-Renal Denervation [ Time Frame: Baseline to 18 months after treatment ]

    For 24-hour blood pressure, we will record the following:

    12-hour daytime Systolic Pressure (mm Hg) 12-hour daytime Diastolic Pressure (mm Hg) 12-hour nighttime Systolic Pressure (mm Hg) 12-hour nighttime Diastolic Pressure (mm Hg)


  17. Change from Baseline in 24-Hour Ambulatory Blood Pressure at 24-months Post-Renal Denervation [ Time Frame: Baseline to 24 months after treatment ]

    For 24-hour blood pressure, we will record the following:

    12-hour daytime Systolic Pressure (mm Hg) 12-hour daytime Diastolic Pressure (mm Hg) 12-hour nighttime Systolic Pressure (mm Hg) 12-hour nighttime Diastolic Pressure (mm Hg)




Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Glomerular filtration rate: 60-15 mls/min as per the modified diet in renal disease formula (Stage 3 and 4 Chronic Kidney Disease)
  • Daytime systolic blood pressure on ambulatory monitor ≥ 135 mm Hg while taking 3 or more anti-hypertensives including a diuretic on maximal dose OR ambulatory monitor systolic blood pressure is <135 but taking 4 or more anti-hypertensives
  • 18 years and above
  • A minimum of 20 mm of length and 4 mm of diameter for renal arteries on CT renal angiogram or formal renal angiogram

Exclusion Criteria:

  • not suitable for renal denervation based on the Indications for Use

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01832233


Locations
Canada, Saskatchewan
Regina Qu'Appelle Health Region
Regina, Saskatchewan, Canada
Sponsors and Collaborators
Saskatchewan Health Authority - Regina Area
Investigators
Principal Investigator: Bhanu Prasad, MD Saskatchewan Health Authority - Regina Area

Responsible Party: Saskatchewan Health Authority - Regina Area
ClinicalTrials.gov Identifier: NCT01832233     History of Changes
Other Study ID Numbers: REB12-73
First Posted: April 16, 2013    Key Record Dates
Last Update Posted: October 24, 2017
Last Verified: October 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Additional relevant MeSH terms:
Kidney Diseases
Renal Insufficiency, Chronic
Urologic Diseases
Renal Insufficiency